Johnson & Johnson Vaccine’s 66% Efficacy Figure Is Better Than It Looks |
| February 02, 2021 | February 2021 Bond Updates |
|
Johnson & Johnson announced that its single-shot Covid-19 vaccine was 66% effective in preventing moderate and severe cases of Covid-19 in its global phase 3 trials. Efficacy varied by region, with the shot proving 72% effective in the U.S., 66% effective in Latin America, and around 57% effective.. |
| View more at: https://www.forbes.com/sites/greatspeculations/2021/02/01/johnson--johnson-vaccines-66-efficacy-figure-is-better-than-it-looks/ |
| Related News |